Serum Uric Acid Level (Short-Term Follow-Up, mg/dL) | |||
---|---|---|---|
Allopurinol | . | . | −2.16 (−3.20 to −1.13) |
0.89 (−1.49 to 3.26) | Benzbromarone | . | −3.05 (−5.19 to −0.91) |
0.55 (−1.03 to 2.13) | −0.34 (−2.79 to 2.11) | Febuxostat | −2.71 (−3.90 to −1.52) |
−2.16† (−3.20 to −1.13) | −3.05* (−5.19 to −0.91) | −2.71† (−3.90 to −1.52) | Placebo |
Serum Uric Acid Level (Long-Term Follow-Up, mg/dL) | ||
---|---|---|
Allopurinol | . | −3.17 (−5.19 to −1.15) |
−0.55 (−3.97 to 2.88) | Febuxostat | −2.62 (−5.39 to 0.15) |
−3.17† (−5.19 to −1.15) | −2.62 (−5.39 to 0.15) | Placebo |
Renal Function (Short-Term Follow-Up, mL/min/1.73 m2) | ||
---|---|---|
Allopurinol | . | 3.07 (0.18 to 5.95) |
2.00 (−2.54 to 6.53) | Febuxostat | 1.07 (−2.43 to 4.57) |
3.07† (0.18 to 5.95) | 1.07 (−2.43 to 4.57) | Placebo |
Renal Function (Long-Term Follow-Up, mL/min/1.73 m2) | ||
---|---|---|
Allopurinol | . | 4.10 (2.66 to 5.54) |
3.70† (1.94 to 5.46) | Febuxostat | 0.40 (−0.60 to 1.40) |
4.10† (2.66 to 5.54) | 0.40 (−0.60 to 1.40) | Placebo |
Systolic Blood Pressure (Short-Term Follow-Up, mm Hg) | ||
---|---|---|
Allopurinol | . | 0.04 (−4.22 to 4.30) |
4.54 (−4.29 to 13.37) | Febuxostat | −4.50 (−12.23 to 3.23) |
0.04 (−4.22 to 4.30) | −4.50 (−12.23 to 3.23) | Placebo |
Systolic Blood Pressure (Long-Term Follow-Up, mm Hg) | ||
---|---|---|
Allopurinol | . | −4.74 (−11.12 to 1.63) |
−3.96 (−10.58 to 2.66) | Febuxostat | −0.78 (−2.57 to 1.01) |
−4.74 (−11.12 to 1.63) | −0.78 (−2.57 to 1.01) | Placebo |
Diastolic Blood Pressure (Short-Term Follow-Up, mm Hg) | ||
---|---|---|
Allopurinol | . | 1.58 (−2.31 to 5.48) |
1.48 (−4.06 to 7.03) | Febuxostat | 0.10 (−3.85 to 4.05) |
1.58 (−2.31 to 5.48) | 0.10 (−3.85 to 4.05) | Placebo |
Diastolic Blood Pressure (Long-Term Follow-Up, mm Hg) | ||
---|---|---|
Allopurinol | . | 0.86 (−3.88 to 5.61) |
2.34 (−2.62 to 7.29) | Febuxostat | −1.47 (−2.90 to −0.04) |
0.86 (−3.88 to 5.61) | −1.47† (−2.91 to −0.04) | Placebo |